{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:30:17Z","timestamp":1787052617383,"version":"build-2736575974"},"reference-count":29,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":214,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Peptide receptor radionuclide therapy (PRRT) with lutetium-177 DOTATATE (177Lu-DOTATATE) is widely adopted as a later-line treatment (second-line or subsequent therapy) for patients with somatostatin receptor-positive neuroendocrine neoplasm. The registration NETTER-1 trial reported a late-onset adverse event of therapy-related myeloid neoplasms (tMNs), including myelodysplastic syndrome (MDS)\/acute myeloid leukemia (AML) in approximately 1% of patients. In this retrospective study, we sought to investigate the frequency of tMN in patients treated with 177Lu-DOTATATE at our institution over the last 8 years and determine the treatment characteristics of patients developing tMN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We accessed the treatment files of patients with neuroendocrine neoplasms treated at our institution between January 2017 and January 2025 for pathology reports of myelodysplasia, leukemia, aplastic anemia and similar hematological disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 173 patients received 177Lu-DOTATATE. A vast majority (77.5%) of them were treated with four therapy cycles. A total of 10\/173 (5.8%) patients (4 males, 6 females) were diagnosed with tMN at a median of 23 months (5.63) after first cycle. One patient developed severe thrombocytopenia, stopped all treatments and was lost to follow-up. Two patients developed acute myelogenous leukemia (AML), six developed myelodysplastic syndrome (MDS), one developed aplastic anemia, and one developed multilineage dyspoiesis (the latter two also deemed to have MDS). Eight out of ten (80%) died after a median duration of 8 months (4.23) from tMN diagnosis. Two patients were diagnosed with AML after 2 and 4 years from the start of first cycle, while 40% of MDS cases were diagnosed by 1 year after cycle 1 of 177Lu-DOTATATE. Additionally, multilineage dyspoiesis was observed at around 5 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The prevalence of tMN was 5.8% in our patient population. We have noted a higher than previously reported percentage of myelodysplasia post-PRRT, especially with additional treatments and longer follow-ups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/eo-26-0038","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:54:14Z","timestamp":1785754454000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-15","source":"Crossref","is-referenced-by-count":0,"title":["Hematological neoplasms after PRRT: experience from long term follow-up of 173 patients in a tertiary center"],"prefix":"10.1530","volume":"6","author":[{"given":"Joao Pedro Thimotheo","family":"Batista","sequence":"first","affiliation":[{"name":"MetroWest Medical Center and Framingham Union Hospital 1 , ,","place":["Framingham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"De La Iglesia","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Washington University School of Medicine 2 , , ,","place":["St. Louis, Missouri, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Washington University School of Medicine 3 , , ,","place":["St. Louis, Missouri, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Prasad","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Washington University School of Medicine 4 , , ,","place":["St. Louis, Missouri, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Shubha","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Washington University School of Medicine 4 , , ,","place":["St. Louis, Missouri, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama","family":"Suresh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Washington University School of Medicine 2 , , ,","place":["St. Louis, Missouri, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Surgery, Washington University School of Medicine 5 , , ,","place":["St. Louis, Missouri, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxia","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Surgery, Washington University School of Medicine 5 , , ,","place":["St. Louis, Missouri, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan","family":"Jacoby","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Washington University School of Medicine 2 , , ,","place":["St. Louis, Missouri, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Urrutia","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Washington University School of Medicine 2 , , ,","place":["St. Louis, Missouri, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8611-2182","authenticated-orcid":true,"given":"Nikolaos A","family":"Trikalinos","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Washington University School of Medicine 2 , , ,","place":["St. Louis, Missouri, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"2026081807214401200_bib1","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026081807214401200_bib2","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"2026081807214401200_bib3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(26)00604-5","article-title":"[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial","volume":"408","author":"Walter","year":"2026","journal-title":"Lancet"},{"key":"2026081807214401200_bib4","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1007\/s00259-021-05236-z","article-title":"Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors","volume":"48","author":"Nicolini","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026081807214401200_bib5","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1002\/cncr.35463","article-title":"Update in the management of gastroenteropancreatic neuroendocrine tumors","volume":"130","author":"Sedlack","year":"2024","journal-title":"Cancer"},{"key":"2026081807214401200_bib6","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00259-020-05127-9","article-title":"Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival","volume":"48","author":"Chantadisai","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026081807214401200_bib7","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1001\/jamaoncol.2020.0078","article-title":"Assessment of therapy-related Myeloid neoplasms in patients with neuroendocrine tumors after peptide receptor radionuclide therapy: a systematic review","volume":"6","author":"Sonbol","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026081807214401200_bib8","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026081807214401200_bib9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2967\/jnumed.117.189712","article-title":"Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177 Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors","volume":"59","author":"Bergsma","year":"2018","journal-title":"J Nucl Med"},{"key":"2026081807214401200_bib10","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.2967\/jnumed.120.258392","article-title":"Semiautomatic tumor delineation for evaluation of64 Cu-DOTATATE PET\/CT in patients with neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume","volume":"62","author":"Carlsen","year":"2021","journal-title":"J Nucl Med"},{"key":"2026081807214401200_bib11","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1200\/JCO.2022.40.16_suppl.4122","article-title":"Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)\u2013final results","volume":"40","author":"Pavlakis","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026081807214401200_bib12","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJM199206253262605","article-title":"Risk of leukemia after chemotherapy and radiation treatment for breast cancer","volume":"326","author":"Curtis","year":"1992","journal-title":"N Engl J Med"},{"key":"2026081807214401200_bib13","first-page":"937","article-title":"The incidence of secondary leukemias","volume":"84","author":"Leone","year":"1999","journal-title":"Haematologica"},{"key":"2026081807214401200_bib14","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00259-018-3945-z","article-title":"Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity","volume":"45","author":"Garske-Rom\u00e1n","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026081807214401200_bib15","doi-asserted-by":"crossref","first-page":"16932","DOI":"10.18632\/oncotarget.24524","article-title":"Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms","volume":"9","author":"Baum","year":"2018","journal-title":"Oncotarget"},{"key":"2026081807214401200_bib16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000506746","article-title":"177Lu-DOTATATE therapy of advanced pancreatic neuroendocrine tumors heavily pretreated with chemotherapy: analysis of outcome, safety, and their determinants","volume":"111","author":"Fr\u00f6ss-Baron","year":"2021","journal-title":"Neuroendocrinology"},{"key":"2026081807214401200_bib17","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1007\/s00259-019-04389-2","article-title":"Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide\/chemoradionuclide therapy (PRRT\/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series","volume":"46","author":"Goncalves","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026081807214401200_bib18","article-title":"Mutant PPM1D - and TP53 -Driven hematopoiesis populates the hematopoietic compartment in response to peptide receptor radionuclide therapy","volume":"6","author":"Singh","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2026081807214401200_bib19","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1002\/cncr.34191","article-title":"Long-term survival and toxicity in patients with neuroendocrine tumors treated with177 Lu-octreotate peptide radionuclide therapy","volume":"128","author":"Kennedy","year":"2022","journal-title":"Cancer"},{"key":"2026081807214401200_bib20","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s00259-018-4158-1","article-title":"Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours","volume":"46","author":"Van Der Zwan","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026081807214401200_bib21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","article-title":"Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors","volume":"42","author":"Bodei","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026081807214401200_bib22","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2026081807214401200_bib23","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.7150\/thno.77219","article-title":"Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors","volume":"12","author":"Jiang","year":"2022","journal-title":"Theranostics"},{"key":"2026081807214401200_bib24","doi-asserted-by":"crossref","first-page":"L17","DOI":"10.1530\/ERC-15-0543","article-title":"High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy","volume":"23","author":"Brieau","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"2026081807214401200_bib25","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2967\/jnumed.112.119347","article-title":"Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate","volume":"54","author":"Sabet","year":"2013","journal-title":"J Nucl Med"},{"key":"2026081807214401200_bib26","doi-asserted-by":"crossref","first-page":"880","DOI":"10.2967\/jnumed.122.264533","article-title":"Evaluation of hepatotoxicity from peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors and a very high liver tumor burden","volume":"64","author":"Gococo-Benore","year":"2023","journal-title":"J Nucl Med"},{"key":"2026081807214401200_bib27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"2026081807214401200_bib28","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2643-3230.BCD-24-0103","article-title":"Therapy-related myeloid neoplasms: complex interactions among cytotoxic therapies, genetic factors, and aberrant microenvironment","volume":"5","author":"Singhal","year":"2024","journal-title":"Blood Cancer Discov"},{"key":"2026081807214401200_bib29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/joim.12893","article-title":"Treatment of myelodysplastic syndrome in the era of next-generation sequencing","volume":"286","author":"Tobiasson","year":"2019","journal-title":"J Intern Med"}],"container-title":["Endocrine Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-26-0038\/523043\/eo-26-0038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-26-0038\/523043\/eo-26-0038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:21:52Z","timestamp":1787052112000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article\/6\/1\/e260038\/77927\/Hematological-neoplasms-after-PRRT-experience-from"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1530\/eo-26-0038","relation":{},"ISSN":["2634-4793"],"issn-type":[{"value":"2634-4793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"e260038"}}